Targeting PAG for cancer immunotherapy
This technology identifies PAG as a cancer immunotherapy target and demonstrates the effectiveness of PAG inhibition using anti-PAG antibodies for tumor clearance.
Unmet Need: Immune checkpoint inhibitor for enhancing T cell-mediated anti-tumor responses
Immune checkpoint inhibitors, such as anti-PD-1, are a relatively new modality that enhances anti-tumor immune responses in T cells of individuals with cancer. Despite great potential, the average response rate for PD-1 binding blockade for most tumors is low, requiring substantial improvement.
The Technology: Anti-PAG antibodies for treating cancer and limiting tumor growth
This technology identifies the PAG protein as a target for cancer immunotherapy and demonstrates the effectiveness of anti-PAG antibody treatment in a tumor-bearing animal model. PAG interactions regulate proper PD-1 signaling; as such, antibodies designed to inhibit PAG successfully prevent PAG/PD-1 interactions, increasing T cell activation, and limiting tumor growth in combination with immune checkpoint inhibitor treatment in mice. This technology has the potential to significantly reduce tumor burden either as a monotherapy or in combination with existing cancer therapies.
Applications:
- Manufacture of anti-PAG antibodies
- Immunotherapy for cancer treatment
- Combination therapy with existing cancer immunotherapies
Advantages:
- Prevents PAG/PD-1 interactions
- Increases T cell activation
- Limits tumor growth in combination with immune checkpoint inhibitor treatment
Lead Inventor:
Patent Information:
Patent Pending (WO/2024/098036)
Related Publications:
Tech Ventures Reference:
IR CU23123
Licensing Contact: Cynthia Lang